NCCN Receives $2 Million in Oncology Research Funding from Boehringer Ingelheim to Investigate Afatinib in Solid Tumors

NCCN recently received a $2 million research grant from Boehringer Ingelheim Pharmaceuticals, Inc. to gain further insight into the use of the investigational compound Afatinib (BIBW 2992) in solid tumors. Investigators from NCCN Member Institutions are eligible to apply for the research funding. FORT WASHINGTON, PA — The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) has been awarded a $2 million grant from Boehringer Ingelheim Pha...
Source: National Comprehensive Cancer Network Oncology Research Program - Category: Cancer & Oncology Source Type: news